Aphase 1/2 trial of high-dose yttrium-90-ibritumomab tiuxetan in combination with high-dose etoposide and cyclophosphamide followed by autologous stem cell transplantation in patients with poor-risk or relapsed non-Hodgkin lymphoma

Blood

Volumn 106, Issue 8, 2005, Pages 2896-2902

  Nademanee, Auayporn ^a   Forman, Stephen ^b   Molina, Arturo ^b   Fung, Henry ^b   Smith, David ^b   Dagis, Andy ^b   Kwok, Cheuk ^b   Yamauchi, Dave ^b   Anderson, Anne Line ^b   Falk, Peter ^b   Krishnan, Amrita ^b   Kirschbaum, Mark ^b   Kogut, Neil ^b   Nakamura, Ryotaro ^b   O'Donnell, Margaret ^b   Parker, Pablo ^b   Popplewell, Leslie ^b   Pullarkat, Vinod ^b   Rodriguez, Roberto ^b   Sahebi, Firoozeh ^b   Smith, Eileen ^b   Snyder, David ^b   Stein, Anthony ^b   Spielberger, Ricardo ^b   Zain, Jasmine ^b   White, Christine ^b   Raubitschek, Andrew ^b   more..

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; ETOPOSIDE; IBRITUMOMAB TIUXETAN; INDIUM 111; RITUXIMAB; MONOCLONAL ANTIBODY; YTTRIUM;

ADULT; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; BONE MARROW BIOPSY; CARDIOTOXICITY; CLINICAL ARTICLE; CLINICAL TRIAL; DOSIMETRY; DRUG TOLERABILITY; FEMALE; FOLLICULAR LYMPHOMA; FOLLOW UP; HISTOLOGY; HUMAN; HYPOTENSION; INFECTION; LARGE CELL LYMPHOMA; LIVER TOXICITY; LUNG DISEASE; MALE; MANTLE CELL LYMPHOMA; MUCOSA INFLAMMATION; NAUSEA; NEUTROPHIL; NONHODGKIN LYMPHOMA; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RADIATION DOSE; RASH; SURVIVAL RATE; THROMBOCYTE COUNT; VOMITING; WHOLE BODY RADIATION; AUTOTRANSPLANTATION; DRUG COMBINATION; IMMUNOLOGY; MIDDLE AGED; POSITRON EMISSION TOMOGRAPHY; PROGNOSIS; RADIOIMMUNOTHERAPY; RECURRENT DISEASE; STEM CELL TRANSPLANTATION;

ADULT; ANTIBODIES, MONOCLONAL; CYCLOPHOSPHAMIDE; DRUG THERAPY, COMBINATION; ETOPOSIDE; FEMALE; HUMANS; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; PROGNOSIS; RADIOIMMUNOTHERAPY; RECURRENCE; STEM CELL TRANSPLANTATION; SURVIVAL RATE; TRANSPLANTATION, AUTOLOGOUS; YTTRIUM RADIOISOTOPES;

EID: 27144463121     PISSN: 00064971     EISSN: 00064971     Source Type: Journal    
DOI: 10.1182/blood-2005-03-1310     Document Type: Article

References (29)

1. Fisher RI, Gaynor ER, Dahlberg S, et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med. 1993;328:1002-1006.
2. Vose JM, Anderson JR, Kessinger A, et al. Highdose chemotherapy and autologous hematopoietic stem-cell transplantation for aggressive non-Hodgkin's lymphoma. J Clin Oncol. 1993;11:1846-1851.
3. Nademanee A, Molina A, Dagis A, et al. Autologous stem cell transplantation for poor-risk and relapsed intermediate-and high-grade non-Hodgkin's lymphoma. Clin Lymphoma. 2000;1:46-54.
4. Philip T, Guglielmi C, Hagenbeek A, et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med. 1995;333:1540-1545.
5. Horning SJ, Negrin RS, Chao NJ, et al. Fractionated total-body irradiation, etoposide, and cyclophosphamide plus autografting in Hodgkin's disease and non-Hodgkin's lymphoma. J Clin Oncol. 1994;12:2552-2558.
6. Weaver CH, Petersen FB, Appelbaum FA, et al. High-dose fractionated total-body irradiation, etoposide, and cyclophosphamide followed by autologous stem-cell support in patients with malignant lymphoma. J Clin Oncol. 1994;12:2559-2566.
7. Stiff PJ, Dahlberg S, Forman SJ, et al. Autologous bone marrow transplantation for patients with relapsed or refractory diffuse aggressive non-Hodgkin's lymphoma: value of augmented preparative regimens - a Southwest Oncology Group trial. J Clin Oncol. 1998;16:48-55.
8. Press OW. Radiolabeled antibody therapy of B-cell lymphomas. Semin Oncol. 1999;26:58-65.
9. Press OW, Eary JF, Appelbaum FR, et al. Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support. N Engl J Med. 1993;329:1219-1224.
10. Press OW, Eary JF, Gooley T, et al. A phase I/II trial of iodine-131-tositumomab (anti-CD20), etoposide, cyclophosphamide, and autologous stem cell transplantation for relapsed B-cell lymphomas. Blood. 2000;96:2934-2942.
11. + B-cell non-Hodgkin's lymphoma. J Clin Oncol. 1999;17:3793-3803.
12. Witzig TE, Gordon LI, Cabanillas F, et al. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. J Clin Oncol. 2002;20:2453-2463.
13. + B-cell lymphoma: long-term follow-up of a phase 1/2 study. Blood. 2004;103:4429-4431.
14. Rastetter W, Molina A, White CA. Expanding role in therapy for lymphomas and autoimmune diseases. Ann Rev Med. 2004;55:503-2004.
15. Vose JM, Bierman PJ, Enke C, et al. Phase I trial of iodine-131 tositumomab with high-dose chemotherapy and autologous stem-cell transplantation for relapsed non-Hodgkin's lymphoma. J Clin Oncol. 2005;23:461-467.
16. Winter JN, Inwards D, Erwin W, et al. Zevalin dose-escalation followed by high-dose BEAM and autologous peripheral blood progenitor cell (PBPC) transplant in non-Hodgkin's lymphoma: early outcome results [abstract]. Blood. 2002;100:411a.
17. Fung HC, Forman SJ, Nademanee A, et al. A new preparative regimen for older patients with aggressive CD 20 positive B-cell lymphoma utilizing standard dose yttrium-90 ibritumomab tiuxetan (Zevalin) radioimmunotherapy (RIT) combined with high-dose BEAM followed by autologous hematopoietic cell transplantation (AHCT): targeted intensification without increased transplantrelated toxicity [abstract]. Blood. 2003;102:248a.
18. Bierman PJ, Vose JM, Anderson JR, et al. Highdose therapy with autologous hematopoietic rescue for follicular low-grade non-Hodgkin's lymphoma. J Clin Oncol. 1997;15:445-450.
19. Freedman AS, Neuberg D, Mauch P, et al. Longterm follow-up of autologous bone marrow transplantation in patients with relapsed follicular lymphoma. Blood. 1999;94:3325-3333.
20. Vose JM, Wahl RL, Saleh M, et al. Multicenter phase II study of iodine-131 tositumomab for chemotherapy-relapsed/refractory low-grade and transformed low-grade B-cell non-Hodgkin's lymphomas. J Clin Oncol. 2000;18:1316-1323.
21. Witzig TE, White CA, Gordon LI, et al. Safety of yttrium-90 ibritumomab tiuxetan radioimmunotherapy for relapsed low-grade, follicular, or transformed non-Hodgkin's lymphoma. J Clin Oncol. 2003;21:1263-1270.
22. Gopal AK, Gooley TA, Maloney DG, et al. Highdose radioimmunotherapy versus conventional high-dose therapy and autologous hematopoietic stem cell transplantation for relapsed follicular non-Hodgkin lymphoma: a multivariable cohort analysis. Blood. 2003;102:2351-2357.
23. Hiddemann W, Unterhalt M, Herrmann R, et al. Mantle-cell lymphomas have more widespread disease and a slower response to chemotherapy compared with follicle-center lymphomas: results of a prospective comparative analysis of the German Low-Grade Lymphoma Study Group. J Clin Oncol. 1998;16:1922-1930.
24. Fisher RI, Dahlberg S, Nathwani BN, et al. A clinical analysis of two indolent lymphoma entities: mantle cell lymphoma and marginal zone lymphoma (including the mucosa-associated lymphoid tissue and monocytoid B-cell subcategories): a Southwest Oncology Group study. Blood. 1995;85:1075-1082.
25. Vose JM, Bierman PJ, Weisenburger DD, et al. Autologous hematopoietic stem cell transplantation for mantle cell lymphoma. Biol Blood Marrow Transplant. 2000;6:640-645.
26. Freedman AS, Neuberg D, Gribben JG, et al. High-dose chemoradiotherapy and anti-B-cell monoclonal antibody-purged autologous bone marrow transplantation in mantle-cell lymphoma: no evidence for long-term remission. J Clin Oncol. 1998;16:13-18.
27. Molina A, Kraft D, Carter N, et al. Autologous stem cell transplantation (ASCT) for mantle cell lymphoma (MCL): a report of 69 patients from City of Hope (COH) and Stanford [abstract]. Blood. 2002;100(suppl 1):182a.
28. Gopal AK, Rajendran JG, Petersdorf SH, et al. High-dose chemo-radioimmunotherapy with autologous stem cell support for relapsed mantle cell lymphoma. Blood. 2002;99:3158-3162.
29. Behr TM, Griesinger F, Riggert J, et al. High-dose myeloablative radioimmunotherapy of mantle cell non-Hodgkin lymphoma with the iodine-131-labeled chimeric anti-CD20 antibody C2B8 and autologous stem cell support: results of a pilot study. Cancer. 2002;94:1363-1372.